The Link Between the Gut Microbiome and Response to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
- 16 September 2020
- journal article
- editorial
- Published by Elsevier BV in European Urology
- Vol. 79 (1), 1-2
- https://doi.org/10.1016/j.eururo.2020.09.001
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung CancerCancer Immunology Research, 2020
- Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint InhibitorsEuropean Urology, 2020
- Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma PatientsEuropean Urology, 2020
- Moving towards personalized treatments of immune-related adverse eventsNature Reviews Clinical Oncology, 2020
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2019
- The gut microbiota influences anticancer immunosurveillance and general healthNature Reviews Clinical Oncology, 2018
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patientsScience, 2018
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patientsScience, 2018
- Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsScience, 2018
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaScience, 2015